The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies

William Harris, Liana Del Gobbo, Nathan L. Tintle

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background and aims A recent 19-cohort meta-analysis examined the relationships between biomarkers of omega-3 fatty acids and risk for coronary heart disease (CHD). That study did not, however, report hazard ratios (HRs) specifically as a function of erythrocyte eicosapentaenoic (EPA) plus docosahexaenoic (DHA) levels, a metric called the Omega-3 Index in which EPA + DHA content is expressed as a percent of total fatty acids. The Omega-3 Index has been used in several recent studies and is a validated biomarker of omega-3 fatty acid tissue levels, but additional data are needed to confirm (or refute) the originally-proposed clinical cut-points of <4% (higher risk) and 8%–12% (lower risk). Methods The present study was therefore undertaken using published data from this meta-analysis to estimate HRs per 1-SD increase in the Omega-3 Index and median quintile values for this metric across 10 of the cohorts for which the needed data were available. Results The overall mean (SD) for the Omega-3 Index in these 10 cohort studies was 6.1% (2.1%), and the HR for a 1-SD increase was 0.85 (95% confidence interval, 0.80–0.91). Median quintile 1 and 5 levels were 4.2% vs. 8.3%, respectively. Based on these values, we estimate that risk for fatal CHD would have been reduced by about 30% moving from an Omega-3 Index of 4%–8%. Conclusions These findings support the use of <4% and >8% as reasonable therapeutic targets for the Omega-3 Index.

Original languageEnglish (US)
Pages (from-to)51-54
Number of pages4
JournalAtherosclerosis
Volume262
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Coronary Disease
Cohort Studies
Biomarkers
Mortality
Meta-Analysis
Adipose Tissue
Fatty Acids
Erythrocytes
Therapeutics

Keywords

  • Biomarker
  • Coronary heart disease
  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Fish oil
  • Meta-analysis
  • Omega-3
  • Omega-3 Index
  • Prospective cohort

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The Omega-3 Index and relative risk for coronary heart disease mortality : Estimation from 10 cohort studies. / Harris, William; Del Gobbo, Liana; Tintle, Nathan L.

In: Atherosclerosis, Vol. 262, 01.07.2017, p. 51-54.

Research output: Contribution to journalArticle

Harris, William ; Del Gobbo, Liana ; Tintle, Nathan L. / The Omega-3 Index and relative risk for coronary heart disease mortality : Estimation from 10 cohort studies. In: Atherosclerosis. 2017 ; Vol. 262. pp. 51-54.
@article{799aa1423f274cbdb8888cb79e37ca09,
title = "The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies",
abstract = "Background and aims A recent 19-cohort meta-analysis examined the relationships between biomarkers of omega-3 fatty acids and risk for coronary heart disease (CHD). That study did not, however, report hazard ratios (HRs) specifically as a function of erythrocyte eicosapentaenoic (EPA) plus docosahexaenoic (DHA) levels, a metric called the Omega-3 Index in which EPA + DHA content is expressed as a percent of total fatty acids. The Omega-3 Index has been used in several recent studies and is a validated biomarker of omega-3 fatty acid tissue levels, but additional data are needed to confirm (or refute) the originally-proposed clinical cut-points of <4{\%} (higher risk) and 8{\%}–12{\%} (lower risk). Methods The present study was therefore undertaken using published data from this meta-analysis to estimate HRs per 1-SD increase in the Omega-3 Index and median quintile values for this metric across 10 of the cohorts for which the needed data were available. Results The overall mean (SD) for the Omega-3 Index in these 10 cohort studies was 6.1{\%} (2.1{\%}), and the HR for a 1-SD increase was 0.85 (95{\%} confidence interval, 0.80–0.91). Median quintile 1 and 5 levels were 4.2{\%} vs. 8.3{\%}, respectively. Based on these values, we estimate that risk for fatal CHD would have been reduced by about 30{\%} moving from an Omega-3 Index of 4{\%}–8{\%}. Conclusions These findings support the use of <4{\%} and >8{\%} as reasonable therapeutic targets for the Omega-3 Index.",
keywords = "Biomarker, Coronary heart disease, Docosahexaenoic acid, Eicosapentaenoic acid, Fish oil, Meta-analysis, Omega-3, Omega-3 Index, Prospective cohort",
author = "William Harris and {Del Gobbo}, Liana and Tintle, {Nathan L.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.atherosclerosis.2017.05.007",
language = "English (US)",
volume = "262",
pages = "51--54",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The Omega-3 Index and relative risk for coronary heart disease mortality

T2 - Estimation from 10 cohort studies

AU - Harris, William

AU - Del Gobbo, Liana

AU - Tintle, Nathan L.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background and aims A recent 19-cohort meta-analysis examined the relationships between biomarkers of omega-3 fatty acids and risk for coronary heart disease (CHD). That study did not, however, report hazard ratios (HRs) specifically as a function of erythrocyte eicosapentaenoic (EPA) plus docosahexaenoic (DHA) levels, a metric called the Omega-3 Index in which EPA + DHA content is expressed as a percent of total fatty acids. The Omega-3 Index has been used in several recent studies and is a validated biomarker of omega-3 fatty acid tissue levels, but additional data are needed to confirm (or refute) the originally-proposed clinical cut-points of <4% (higher risk) and 8%–12% (lower risk). Methods The present study was therefore undertaken using published data from this meta-analysis to estimate HRs per 1-SD increase in the Omega-3 Index and median quintile values for this metric across 10 of the cohorts for which the needed data were available. Results The overall mean (SD) for the Omega-3 Index in these 10 cohort studies was 6.1% (2.1%), and the HR for a 1-SD increase was 0.85 (95% confidence interval, 0.80–0.91). Median quintile 1 and 5 levels were 4.2% vs. 8.3%, respectively. Based on these values, we estimate that risk for fatal CHD would have been reduced by about 30% moving from an Omega-3 Index of 4%–8%. Conclusions These findings support the use of <4% and >8% as reasonable therapeutic targets for the Omega-3 Index.

AB - Background and aims A recent 19-cohort meta-analysis examined the relationships between biomarkers of omega-3 fatty acids and risk for coronary heart disease (CHD). That study did not, however, report hazard ratios (HRs) specifically as a function of erythrocyte eicosapentaenoic (EPA) plus docosahexaenoic (DHA) levels, a metric called the Omega-3 Index in which EPA + DHA content is expressed as a percent of total fatty acids. The Omega-3 Index has been used in several recent studies and is a validated biomarker of omega-3 fatty acid tissue levels, but additional data are needed to confirm (or refute) the originally-proposed clinical cut-points of <4% (higher risk) and 8%–12% (lower risk). Methods The present study was therefore undertaken using published data from this meta-analysis to estimate HRs per 1-SD increase in the Omega-3 Index and median quintile values for this metric across 10 of the cohorts for which the needed data were available. Results The overall mean (SD) for the Omega-3 Index in these 10 cohort studies was 6.1% (2.1%), and the HR for a 1-SD increase was 0.85 (95% confidence interval, 0.80–0.91). Median quintile 1 and 5 levels were 4.2% vs. 8.3%, respectively. Based on these values, we estimate that risk for fatal CHD would have been reduced by about 30% moving from an Omega-3 Index of 4%–8%. Conclusions These findings support the use of <4% and >8% as reasonable therapeutic targets for the Omega-3 Index.

KW - Biomarker

KW - Coronary heart disease

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Fish oil

KW - Meta-analysis

KW - Omega-3

KW - Omega-3 Index

KW - Prospective cohort

UR - http://www.scopus.com/inward/record.url?scp=85019099357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019099357&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2017.05.007

DO - 10.1016/j.atherosclerosis.2017.05.007

M3 - Article

C2 - 28511049

AN - SCOPUS:85019099357

VL - 262

SP - 51

EP - 54

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -